2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

907. Outcomes Research: Plasma Cell Disorders: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Bioinformatics, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Transfusion, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Quality Improvement, Quality of Care, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4549 Early bone-modifying agent utilization and skeletal outcomes by baseline skeletal involvement in multiple myeloma: A real-world trinetx study

Ahmad Al-Alwan, MD, Mohammed Aloqaily, MD2, Osama Mohiuddin, MD3, Moath Albliwi, MD4, Naheed Alam, MD5
1 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
2 University of Maryland Medical Center, Baltimore, Maryland, United States
3 Integers Health, Oklahoma, Oklahoma, United States
4 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
5 Erie County Medical Center, Buffalo, New York, United States

Background

Bone-modifying agents (BMAs) are recommended as supportive care for patients with active multiple myeloma (MM) undergoing systemic therapy, regardless of whether lytic bone disease is detected. Despite these established guidelines, the real-world usage of BMAs remains suboptimal. We evaluated early utilization of BMAs and the subsequent clinical outcomes in MM patients, comparing those with documented baseline skeletal involvement with those without.


Methods

We conducted a retrospective cohort study utilizing the TriNetX US Collaborative Network, which encompasses 71 healthcare organizations. The study included adults diagnosed with active MM who initiated systemic therapy with bortezomib, carfilzomib, ixazomib, pomalidomide, daratumumab, or lenalidomide. The index date was defined as the first recorded use of a qualifying MM-directed systemic therapy. Baseline skeletal involvement was identified through the presence of osteolysis or pathologic fractures related to neoplastic disease within 365 days prior to or on the index date. Patients without either diagnosis during this timeframe served as the comparator cohort. Cohorts were balanced 1:1 through propensity score matching using age, race/ethnicity, chronic kidney disease, and osteoporosis without an active pathologic fracture. The primary outcome measured was the administration of a bone-modifying agent (zoledronic acid, pamidronate, or denosumab) within 90 days of treatment initiation. Secondary outcomes included all-cause mortality over one year and, in an exploratory analysis, the incidence of pathologic fractures between days 91 and 365 among patients without a prior qualifying fracture.


Results:

Before matching, 3,800 patients with documented baseline skeletal involvement and 53,368 without documented involvement were identified. After propensity-score matching, 3,763 patients were included in each cohort. BMA utilization within 90 days remained low despite guideline recommendations and was significantly higher among patients with documented skeletal involvement compared with those without (1,638/3,763 [43.5%] vs 979/3,763 [26.0%]; risk ratio [RR], 1.67; 95% CI, 1.57–1.79; absolute risk difference, 17.5 percentage points; P<0.001). One-year survival proportions were close between groups (87.5% vs 88.9%), although time-to-event analysis showed a modestly increased risk of mortality among patients with baseline skeletal involvement (hazard ratio [HR], 1.16; 95% CI, 1.01–1.33; log-rank P=0.039). In the exploratory fracture analysis excluding patients with prior pathologic fracture, incident fracture occurred in 33 of 443 patients (7.4%) with baseline skeletal involvement compared with 146 of 3,084 patients (4.7%) without documented involvement (RR, 1.57; 95% CI, 1.09–2.27; P=0.015).


Conclusions:

Initiation of bone-modifying agent (BMA) therapy among patients with active MM was notably lower than the expectations set by clinical guidelines, even among those with documented skeletal involvement. Notably, around a quarter of patients without documented baseline skeletal involvement received BMA within the first ninety days. The 17.5-percentage-point lower rate of early BMA use among patients without identified baseline bone lesions suggests that these patients may be less likely to be recognized as candidates for BMA therapy, resulting in missed opportunities for timely treatment initiation.These findings are consistent with smaller contemporary real-world studies, where 71%-78% of patients eventually received a BMA but only 41%-53% did so within the first three months. Together, they point to a real gap between guideline recommendations and real-world practice, and support efforts to improve adherence to supportive care pathways regardless of documented baseline skeletal involvement. These real-world EHR findings warrant prospective confirmation. 

Ahmad Al-Alwan, MD: No relevant conflicts of interest to declare.